We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)
News

NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)

NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)
News

NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NovAliX has announced that it has entered into a multi-year drug research collaboration in the field of trisomy 21 with the Fondation Jérôme Lejeune.

NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the cystathionine-beta-synthase (CBS).

Indeed inhibition of CBS over-expression has been associated with restoration of cognitive impairment in animal models afflicted with trisomy.

"We look forward to progressing our research programs for treating trisomy 21 leveraging NovAliX expertise in structure-based drug design and capabilities in advanced lead generation methodologies" said Dr Henri Bléhaut, Chief Scientific Officer at the Fondation Jérôme Lejeune.

Stephan Jenn, President of NovAliX, said "we are very pleased to investigate a novel research approach for the Down syndrome (trisomy 21) and to support the Fondation Jérôme Lejeune in its efforts to improve patients conditions".

Advertisement